Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Subcutaneous MabCampath (alemtuzumab) and oral Fludara (fludarabine phosphate) for the treatment of refractory or relapsed chronic lymphocytic leukemia in 2nd or 3rd line of treatment: A pilot trial (FLUSALEM) for the determination of safety, efficacy and molecular profiling for the prediction of response

Trial Profile

Subcutaneous MabCampath (alemtuzumab) and oral Fludara (fludarabine phosphate) for the treatment of refractory or relapsed chronic lymphocytic leukemia in 2nd or 3rd line of treatment: A pilot trial (FLUSALEM) for the determination of safety, efficacy and molecular profiling for the prediction of response

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FLUSALEM
  • Most Recent Events

    • 06 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.
    • 10 Dec 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top